Clinical Trials for Liver Cancer

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic HCC (or mixed HCC-CCA), ECOG 0–1 and Child-Pugh A–B7, receive a single-fraction vGRID SBRT dose-escalation (27–47 Gy; de-escalation to 40 Gy in 5 fractions if needed) targeting part of the tumor with high dose while respecting liver/GI constraints. Standard atezolizumab (PD-L1 inhibitor) starts 12–16 days post-SBRT with bevacizumab held for cycle 1 to reduce GI risk.

ClinicalTrials.gov ID: NCT05727787

Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adolescents and adults with metastatic adrenocortical carcinoma with symptomatic liver metastases and extrahepatic disease, ECOG 0–1, and no prior PD-1/PD-L1/CTLA-4 therapy, evaluating ablative radiotherapy to liver lesions followed by pembrolizumab. Pembrolizumab is an anti–PD-1 monoclonal antibody intended to enhance antitumor T-cell activity, with the RT combination aiming to potentiate systemic immune responses.

ClinicalTrials.gov ID: NCT06066333

A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, locally advanced/metastatic HCC and Child-Pugh B7–B8 cirrhosis, ECOG 0–2, and no prior systemic therapy receive either atezolizumab plus bevacizumab (anti–PD-L1 + anti-VEGF) or atezolizumab alone, with emphasis on safety/tolerability in this higher-risk population. Excludes high bleeding risk (e.g., recent/active variceal bleeding), significant autoimmune disease, prior checkpoint inhibitors, and TIPS for the combo cohort.

ClinicalTrials.gov ID: NCT06096779

Regorafenib and Yttrium-90 Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable HCC (Child-Pugh A–B7), no prior systemic therapy, and suitable anatomy for Y-90 TARE receive combined Y-90 radioembolization (TheraSphere) plus regorafenib, an oral multikinase inhibitor of VEGFR1–3, TIE2, KIT, RET, and RAF. Excludes major extrahepatic disease and significant comorbidities; aims to assess disease control and safety.

ClinicalTrials.gov ID: NCT06902246

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adults with biopsy-proven NSCLC (excluding EGFR/ALK/ROS1/RET-altered tumors) or melanoma with radiographic liver metastases, ECOG 0–2, eligible for standard PD-1/PD-L1 checkpoint inhibitor–based therapy (± chemotherapy and/or CTLA-4 inhibition per routine practice). All patients receive standard systemic therapy plus investigational low-dose liver radiation delivered in the week before cycles 1, 2, and 3 to potentially modulate the hepatic immune microenvironment and enhance checkpoint inhibitor efficacy.

ClinicalTrials.gov ID: NCT07225036

Phase 1, Single-site, Single-arm, Clinical Imaging, and Blood-based Biomarker Trial Utilizing 18F-FSPG PET to Guide Therapy in Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with imaging- or pathology-confirmed hepatocellular carcinoma meeting LI-RADS criteria who are candidates for Y90 radioembolization monotherapy. Patients receive standard Y90, with investigational 18F-FSPG PET/CT (a glutamate analog tracer reflecting system xC−/redox-related amino acid transport activity) plus paired ctDNA blood sampling before and after treatment to assess early prediction/detection of response or resistance versus standard imaging over 12 months.

ClinicalTrials.gov ID: NCT07116486

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial targets adults with stage IV NSCLC involving liver metastases, excluding those with EGFR or BRAF mutations and prior liver radiation, to evaluate the impact of adding liver stereotactic ablative radiotherapy (L-SABR) to a standard regimen of anti-PD-(L)1 based immunotherapy and optional platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05657873

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates the combination of Trans-Arterial Tirapazamine Embolization (TATE) and Pembrolizumab in patients with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) who have liver metastases and have progressed after prior therapies. TATE delivers the hypoxia-activated prodrug Tirapazamine to liver tumors, while Pembrolizumab, an immune checkpoint inhibitor, blocks the PD-1 pathway to enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT04701476

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial investigates the safety and feasibility of combining liver SBRT with the immune checkpoint inhibitor Pembrolizumab, which targets PD-1, in adult patients with metastatic non-small cell lung cancer and liver metastases who are eligible for this immunotherapy.

ClinicalTrials.gov ID: NCT05430009